A Review on the Morbidity and Mortality in COVID-19 Patients with Pre-existing Asthma in India

Abstract

Abstract: The global epidemiology of asthma shows a complex association with COVID-19 regarding morbidity, comorbidity, and mortality. This study aimed to shed light on the relationship between COVID-19 and pre-existing asthma, specifically within the Indian context, considering the large population and significant burden of asthma. To review and integrate the available data on morbidity, comorbidity, and mortality outcomes of COVID-19 patients with pre-existing asthma in India, fulltext articles were searched between December 1st, 2019 to April 20th, 2023, in Science Direct and PubMed on studies with COVID-19 patients suffering from asthma. A total of 893 articles were screened based on a certain inclusion criterion, and 15 full-text articles were eligible for the review. The studies included 10,239 participants comprising 73.47% (n= 7523) of COVID-19 patients. More males (n= 4993) were affected by COVID-19 infection compared to females (n= 2510). A total of 262 (3.48%) COVID-19 patients had pre-existing asthma, and 58 deaths (0.77%) were observed among them. South India exhibited the highest number of COVID-19 patients with asthma comorbidity (5.38%), while North India had the lowest number of COVID-19-infected patients with preexisting asthma (1.69%). The highest mortality was found among patients with asthma across India (7.14%), and the lowest mortality (0.12%) was reflected in cases from North India. This review showed less asthma comorbidity and mortality cases in COVID-19 patients in India. The study indicated higher COVID-19 infection rates in males. Regional disparities were observed in COVID-19 patients with asthma comorbidity and mortality. In contrast, few studies have reported higher asthma comorbidity and mortality in COVID-19 patients with pre-existing asthma.